Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-β-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.

中文翻译：

---

(1,3)-β-D-葡聚糖在接受免疫球蛋白和治疗性抗体治疗的肿瘤血液病患者中的高假阳性率

免疫球蛋白和/或治疗性抗体制剂与定期筛查真菌感染的肿瘤血液病患者的 (1,3)-β-D-葡聚糖 (BDG) 检测的高假阳性率相关。BDG 监测的好处应与导致该人群不必要的调查和成本的假阳性测试的风险相平衡。